Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Therapeutic potential of stromal vascular fraction in early diabetic nephrotoxicity: a histomorphometric and immunohistochemical analysis in a type 2 diabetes rat model.

Hamoud AE., Wanas H., Bayoumi AH., Shuaib DM., Zickri MB., Gouda MAA.

Animal Study on Type 2 Diabetes, Chronic Kidney Disease, published in Folia Morphol (Warsz) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Folia Morphol (Warsz) (2025)
Country
Poland
Reported sample size
—
Source database
PubMed
PMID
39821782
DOI
10.5603/fm.103545

Abstract (original English)

Background Diabetic nephropathy (DN), a common complication of type 2 diabetes (T2D), significantly contributes to end-stage kidney disease (ESKD). Despite conventional treatments aimed at slowing disease progression, there is a pressing need for novel therapies. This study evaluates the potential therapeutic impact of adipose tissue-derived stromal vascular fraction (SVF) on early diabetic nephrotoxicity in a rat model. Materials and methods Thirty-one male albino rats were divided into control and diabetic groups, with the latter further split into untreated (T2Da) and SVF-treated (T2Db) subgroups. Biochemical, histological, immunohistochemical, and morphometric analyses were conducted. Results We demonstrated that SVF treatment reduced oxidative stress, lowered serum creatinine, and improved renal architecture by mitigating fibrosis and cellular infiltration, suggesting enhanced tissue regeneration and reduced inflammation. SVF also facilitated cellular repair, indicated by increased endothelial cell proliferation and reduced glomerular damage. Conclusions This study underscores SVF's potential as a promising regenerative approach for managing early-stage DN, warranting further research to elucidate its mechanisms.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMaleDiabetic NephropathiesDiabetes Mellitus, Type 2RatsDiabetes Mellitus, ExperimentalStromal Vascular FractionImmunohistochemistryOxidative StressKidney

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research